It was found that AP-1 and c-Fos increase in BC cells upon acquired resistance to palbociclib, and that AP-1 blockade (by RNA interference) combined with palbociclib could effectively inhibit cell proliferation and simultaneously decrease p-Rb and CDK2 protein levels [143]. Here, JUN is linked to breast cancer.